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Abstract.  We have previously identified three distinc- 
tive amino acid sequences from type IV collagen 
which specifically bound to heparin and also inhibited 
the binding of heparin to intact type IV collagen. One 
of these chemically synthesized domains, peptide 
Hep-I, has the sequence TAGSCLRKFSTM and 
originates from the al(noncollagenous [NC1]) chain of 
type IV collagen (Koliakos, G.  G., K. K. Koliakos, 
L. T.  Furcht, L. A.  Reger,  and E.  C. Tsilibary.  1989. 
J.  Biol. Chem. 264:2313-2323).  We describe in this 
report that this same peptide also bound to intact type 
IV collagen in solid-phase assays,  in a dose-dependent 
and specific  manner. Interactions between peptide 
Hep-I and type IV collagen in solution resulted in in- 
hibition of the assembly process of this basement 
membrane glycoprotein. Therefore, peptide Hep-I 
should represent a major recognition site in type IV 
collagen when this protein polymerizes to form a net- 
work. In addition, solid phase-immobilized peptide 
Hep-I was able to promote the adhesion and spreading 
of bovine aortic endothelial cells.  When present in so- 
lution, peptide Hep-I competed for the binding of 
these cells to type IV collagen- and NC1  domain- 
coated substrata in a dose-dependent manner. Further- 
more, radiolabeled peptide Hep-I in solution also 
bound to endothelial cells in a dose-dependent and 
specific  manner. The binding of radiolabeled Hep-I to 
endothelial cells could be inhibited by an excess  of un- 
labeled peptide. Finally, in the presence of heparin or 
chondroitin/dermatan sulfate glycosaminoglycan side 
chains, the binding of endothelial cells to peptide 
Hep-I and NC1  domain-coated substrates was also in- 
hibited. We conclude that peptide Hep-I should have a 
number of functions. The role of this type IV 
collagen-derived sequence in such diverse phenomena 
as self-association, heparin binding and cell binding 
and adhesion makes Hep-I a crucial domain involved 
in the determination of basement membrane ultrastruc- 
ture and cellular interactions with type IV collagen- 
containing matrices. 
T 
YPE  IV collagen,  a glycoprotein of basement  mem- 
branes, has been described to have several important 
biological functions. A major function is the ability to 
self-assemble to a polymer with the form of a lattice (30, 
36-39).  Type IV collagen not only forms the main structural 
framework of  most basement membranes, but also serves for 
the binding of other basement membrane components. For 
example, laminin (8, 20), heparan sulfate proteoglycan (13, 
20), and entactin/nidogen (12) have  been reported to bind to 
type IV collagen. An additional important function of type 
IV collagen is the ability to promote cell adhesion of various 
cell  types,  therefore  serving  as  an  adhesive  protein,  like 
laminin (1,  10,  16, 23). 
To better  understand  several functions of this basement 
membrane collagen, we have examined the intact molecule 
and the major proteolytic noncollagenous (NC1)  ~  and triple 
helix-rich domains  (both from the  al[IV]  and the  a2[IV] 
chains) insofar as binding to cell surfaces (10, 16) is con- 
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1. Abbreviations  used in this paper:  EHS, Engel-Holm-Swarm; NC1, non- 
collagenous. 
cerned. We have also examined the binding of heparin to in- 
tact type IV collagen, the above-mentioned proteolytic do- 
mains and peptide sequences from these domains (both from 
the al[IV] and the a2[IV] chains). Previously three discrete 
amino acid sequences of type IV collagen were described 
that specifically bind to heparin and also inhibit the binding 
of heparin to type IV collagen (19). In the present report, we 
extend our earlier observations and describe additional func- 
tions of one heparin-binding  peptide,  peptide Hep-I.  This 
peptide, which originates from the al(NCI) chain (position 
49-60 from the carboxyterminal area), also binds to type IV 
collagen and therefore should mediate, in part, the assembly 
process of this glycoprotein. In addition, we report here that 
peptide Hep-I also promotes the adhesion and spreading of 
bovine aortic endothelial cells and specifically binds to the 
surface of these cells. 
Materials and Methods 
Isolation of 1~pe IV Collagen and Isolated 
NC1 Domain 
Type IV collagen was isolated from the Engelbreth-Holm-Swarm (EHS) tu- 
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The concentration of type IV collagen was determined by the method of 
Waddell (33,  34). 
The main (NC1) domain of type IV collagen was isolated by collagenase 
digestion of EHS-derived type IV collagen as described elsewhere (19, 30, 
31). The concentration of isolated NC1 domain of type IV collagen was de- 
termined by the method of Lowry (22). 
The major triple helical fragment of type IV collagen was isolated by a 
light digestion of EHS-derived type IV collagen with pepsin as reported 
elsewhere (16, 19). The concentration of the triple helical, pepsin-derived 
fragment (which lacks the NCI domain) was determined by the method of 
Waddell  (33,  34). 
Peptide Synthesis and Purification 
Peptides were synthesized on a solid phase support resin according to the 
technique of Barany and Merrifield (2,  19). The synthesized peptides were 
deprotected and released as reported previously (19). Peptides were checked 
for purity by HPLC, amino acid analysis and amino acid sequencing. In this 
study, we used interchangeably HPLC-purified and nonpurifled peptides; 
however, in all  cases, the biological activity of each peptide purified by 
HPLC was tested and found to be similar to that of  the nonpurified peptides. 
lodination of Peptides 
Several peptides were synthesized with an added tyrosine residue at their 
carboxy end and were then labeled with 125I-Na (New England Nuclear, 
Boston, MA) by using the chloramine T method (18). Radiolabeled peptides 
were purified on SEP-PAK C-18 columns (Waters Associates, Milford, MA) 
and eluted with 50% acetonitrile in water containing 0.1% (vol/vol) TCA. 
Eluted peptides were lyophilized and  stored at  -70°C  in a  nitrogen at- 
mosphere until further use. 
Coupling of Peptides to Ovalbumin 
Peptides Hep-I and 1 were coupled to ovalbumin via their cystein residues 
after activation of the ovalbumin by m-maleimido benzoyl-N-hydroxysuc- 
cinimide ester, according to the method of Liu et al.  (21). 
Assays  for the Binding of Peptide Hep-I to 
1~pe IV Collagen 
Solid Phase Binding Assays. 50 p.l/well of type IV collagen (at 60/.tg/m]), 
the pepsin-derived major triple helix-rich domain of type IV collagen (at 
52  /~g/ml),  the tuajor dimeric NCI  fragment of type IV collagen (at 20 
~g/ml) and BSA (at 8 p.g/ml) in PBS containing 0.02%  azide were coated 
onto 96-well Immulon plates by drying at 29°C. We reported previously 
that, under these conditions, 40-50% of each added protein or fragment ad- 
hered to Immulon 1 plates (19).  The plates were then blocked with BSA 
(19,  32),  and increasing concentrations of 50 #l of 125I-Hep-I or t25I-pep- 
tide 1 (a control peptide) were added in a solution containing PBS and 2 
mg/ml BSA, pH 7.4,  and allowed to interact at 37°C for 2 h. The plates 
were then washed and the remaining bound radioactivity was solubilized 
and quantitated as described previously (19, 32). 
In competition assays,  a  constant amount of 125I-peptide (specific or 
control) was mixed with increasing concentrations of the corresponding un- 
labeled (specific or control) peptide and the experiment was otherwise per- 
formed as described above. The maximal excess of unlabeled peptide used 
was 400-fold. 
These solid phase-binding assays were repeated a minimum of five times 
triplicate. 
Rotary Shadowing Assays. The following solutions were then prepared 
in PBS: (a) type IV collagen only (250 ttg/ml); or (b) type IV collagen (25"0 
/~g/m]) containing either peptide Hep-I or any one of the control peptides, 
peptide 1 and peptide 4, at 25, 50,  100, 200, 400, and 800 #g/rnl. 200 ~1 
of each of the incubated samples were subsequently incubated at 37°C for 
1 h. Aliquots of the samples (containing 10-15/~g type IV collagen each) 
were then processed for rotary shadowing and examined by electron micros- 
copy as described in earlier reports (19, 30-32). 
Turbidity Assays. The following solutions were prepared: (a) type IV 
collagen only (at 250/xg/ml); (b) type IV collagen (250 ~g/rnl) containing 
isolated NC1 domain (20 ~tg/ml); (c) type IV collagen (250/~g/ml) contain- 
ing isolated NC1 domain (20 p.g/ml) and peptide Hep-I or any of the control 
peptides (100  ~glm]). The development of turbidity by these mixtures at 
37°C was followed as described in earlier reports (30-32). 
Assays for Interactions between Peptide Hep-I and 
Endothelial Cells 
Bovine aortic endothelial cells were obtained from calf aortas and cultured 
and prepared for cell adhesion experiments as described elsewhere (16). En- 
dothelial cells used in binding experiments were consistently derived from 
early passages (<15  passages were used under our experimental condi- 
tions). 
Solid Phase-binding Assays 
Direct Cell-binding Assays. For these experiments, 96-well  Immulon-I 
plates were coated with the protein, fragment, or peptide of interest at a 
range of concentrations. The wells were then treated with a solution con- 
taining 2 mg/ml BSA in PBS (pH 7.4) for 2 h, at 37°C. [35S]Methionine- 
labeled bovine aortic endothelial cells (0.5  mCi/10  m],  overnight) were 
washed three times with DME and were resuspended in DME containing 
2 mg/ml BSA and 25 mM Hepes. The ceils (,'°5,000  cells/well) were then 
added in the same buffer and were incubated at 37°C for 30-60 min. The 
plates were then washed with 200 #1 of the same buffer three times and the 
bound radioactivity was released with lysis buffer and quantitated with a 
scintillation counter (LS 3801; Beckman Instruments, Inc., Palo Alto, CA). 
Competition Solid Phase Cell-binding Assays 
Competition of Cell Binding in the Presence of Peptides. 96-well, Im- 
mulon-I plates were coated in this instance with type IV collagen at  10 
#g/ml, isolated NCI domain at 20 ~g/ml, and BSA at 8/.tg/ml in PBS. The 
assay was then performed as described above, with the following modifica- 
tions. The cell-containing buffer was mixed with an equal volume of serial 
dilutions of peptide Hep-I or control peptide in the same buffer.  The mix- 
tures were incubated for 15 min at room temperature, were then added (100 
#l/well) in the specific substrate-coated wells, and were further incubated 
for 60 min at 37°C. At the end of the incubation, the plates were washed, 
and bound radioactivity was solubilized and quantitated by scintillation 
counting. 
Competition of Cell-binding in the Presence of Heparin and Chon- 
droitin/Dermatan Sulfate Side Chains. For these experiments, 96-well Im- 
toulon-1 plates were coated with 50 #l/well of a solution of PBS containing 
(a) type IV collagen at  1,  10, or 60 tzg/ml;  (b) isolated NC1 domain (di- 
meric) at 20 or 60 ttg/ml; and (c) peptide Hep-I at 50,  100, or 200 ~g/ml, 
and  further treated as  described above.  [35S]methionine-labeled  bovine 
aortic endothelial cells were suspended in DME containing 25 mM Hepes 
and 2 mg/ml BSA (pH 7.4) at a concentration of 105 cells/ml. 
The resuspended endothelial cells were then mixed with an equal volume 
of serial dilutions of heparin or chondroitin/dermatan sulfate (Sigma Chem- 
ical Co., St. Louis, MO) in the same buffer.  100/zl from each mixture (con- 
taining ,'~5,000 cells) were added in the specifc substrata-coated wells and 
were incubated for 1 h at 37°C.  At the end of the incubation period, the 
plates were washed, and the remaining bound radioactivity was solubilized 
and quantitated by scintillation counting. 
Most of the control peptides (Table I) were tested in two or more of the 
direct and competition solid-phase, cell binding assays. All the cell-binding 
assays (direct or competition) were repeated a minimum of five times in 
triplicate. 
Assays for the Binding of mI-Hep-I to Endothelial 
Cells in Solution 
Direct Binding. Unlabeled bovine aortic endothelial cells were suspended 
in DME containing 25  mM Hepes and 2  mg/m] BSA (pH 7.4)  at  "~105 
cells/m]. 
A constant amount of t25I-Hep-I ("~1 t~g) was mixed with 250 #1 of un- 
labeled peptide Hep-I (4 mg/ml in the same buffer), and the mixture was 
serially diluted in the same buffer.  Subsequently, aliquots of 50 ~tl (",,5,000 
cells) of endothelial cells were added in Eppendorf tubes, followed by 50 
p.l of each peptide dilution at 0°C, and the samples were incubated at 4°C 
for 20 min. 900 #1 of the same buffer were then added per Eppendorf tube, 
and the cells were pelleted by centrifugation in a microfuge (Beckman In- 
struments, Inc.), at 4°C (5 min, 500 g). The cells were washed three times 
and the remaining radioactivity was quantitated  with a  gamma counter 
(Gamma Trac-l193; TM Analytic Inc., Elk Grove Village, IL). 
Competition of the Binding of uJI-Hep-I to Endothelial Cells by Un- 
labeled Peptide Hep-I or Control Peptides in Solution. Unlabeled peptide 
Hep-I or control peptide ET-2 was serially diluted from a starling concen- 
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peptide  Hep-II  LAGSCLARFSTM  a2(IV)  19 
peptide- 1  DPLCPPGTKIL  a 1  (IV)  19 
peptide-4  MFKKPTPSTLKAGELR  a 1  (IV)  19 
peptide  ET-2  GDSRTITTKGERGQP  a2(IV)  (561-565  this report 
from NH2:  interruption) 
peptide J-61  GFPGSRGDTGPP  al(IV)  10 
GRGDSP  Fibronectin;  cell binding  26 
domain 
GRGDTP  a2(I)  3 
tration of 2  mg/ml in DME containing 25 mM Hepes and 2 mg/ml BSA 
(pH 7.4). 5/zl (•5/zg)  of mSl-peptide Hep-I were then added to each serial 
dilution. Aliquots of ~5,000 endothelial cells in the same buffer were added 
in Eppendorf tubes followed by 50 #1 of each peptide dilution at 0°C. The 
cell-peptide mixtures were then incubated for 20 min at 4°C, the cells were 
pelleted and washed, and the binding of 125I-Hep-I in each case was quanti- 
tated. In these competition-binding assays, the excess of unlabeled control 
or Hep-I peptide was 400-fold at the highest peptide concentration. These 
assays (direct and competition) were repeated a minimum of three times in 
quadruplicate. Cell viability in the cell-binding assays was tested based on 
exclusion of trypan blue dye and was found in all cases to be >95%. 
Diaphot  inverted  phase  light  microscope  for  spreading.  Spreading  was 
quantitated based on the appearance of cells: a prerequisite for cells to be 
considered "spread" was a totally smooth, flattened appearance that indi- 
cated complete spreading. Rounded or partially flattened cells were consid- 
ered to be in the category of nonspread cells• This type of experiment was 
performed in quadruplicate• 
Assays for Cell Spreading in Response to 
Peptide Hep-I 
These experiments were performed in 24-well tissue culture plates (Costar, 
Cambridge, MA) which had been previously coated with 350/~1 type IV 
collagen (10 ~g/ml), BSA (5 #g/ml), or peptide Hep-I (20 #g/ml) with the 
above-mentioned methodology (to achieve similar percent of protein and 
peptide bound to the tissue culture plastic when compared to the amount 
bound to Immulon-1, 96-well plates). The plates were blocked with BSA 
(19, 32), and unlabeled bovine aortic endothelial cells were then incubated 
with the coated substrates in DME containing 25 mM Hepes and 2 mg/ml 
BSA (pH 7.4)  for 30-90 min at 37°C (",,35,000 cells/well). At the end of 
the incubation time, the plates were washed three times and the cells were 
fixed by adding 1% glutaraldehyde in PBS, at room temperature. The re- 
maining bound cells were examined by direct visualization with a  Nikon 
Results 
Q,. 
The Binding of Peptide Hep-I to ~pe IV Collagen 
When  ~25I-peptide Hep-I was tested for binding to type IV 
collagen coated onto plastic,  it bound in a dose-dependent 
and saturable  manner.  Approximately 70 ng of the radiola- 
beled peptide were bound to type IV collagen ("~1.2/~g coated 
on plastic; reference 19) at the plateau  level. This apparent 
saturation indicated that the binding should be specific (Fig. 
1 A). Further evidence for the specific nature of the binding 
between type IV collagen and peptide Hep-I was obtained by 
experiments  in which the binding  of '25I-Hep-I was efficient- 
ly competed in the presence of an excess of unlabeled peptide 
Hep-I (Fig.  1 A). 
Peptide  1 (Table I), a control peptide of similar length and 
Peptide  added (p.g/sample) 
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Table L  Control and Biologically  Active Peptides Used 
Peptide  Sequence  Origin  Reference 
Peptide Hep-I bound (mM) 
i 
7O 
Figure 1.  (A) Direct binding of peptide Hep-I to solid phase-type IV collagen and competition by unlabeled peptide. Type IV collagen 
at 60/~g/ml was coated onto 96-well plates (1.3 t~g bound/well). For the direct binding, increasing concentrations of 125I-labeled  peptide 
Hep-I (m) or control peptide 1 (A) were added (50 #l/well of serial dilutions from a starting concentration of 2 mg/ml) and were allowed 
to incubate for 2 h at 37°C. The radioactivity  that remained bound after incubation and washing was plotted as nanograms of peptide bound 
per actual amount of peptide added per well. For competition, the binding of 5/zg ~25I-labeled  peptide Hep-I (n) or control peptide (zx) 
in the presence of increasing concentrations of unlabeled peptide Hep-I or peptide 1, respectively, was tested by incubation at 37°C for 
2 h. The highest concentration of unlabeled peptide used was 2 mg/ml (400-fold excess). The remaining bound radioactivity  after incubation 
and washes was plotted as percent radioactivity bound per actual amount of peptide added per well. (B) Scatchard analysis of a typical 
direct solid-phase binding experiment in which increasing concentrations of ~25I-peptide Hep-I were added to type IV collagen-coated 
wells (1.3 Izg of type IV collagen coated/well). 10 different concentrations were used in triplicate wells to allow for quantitation of the 
binding. 
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Figure 2. Binding of ~25I-Hep-I to solid phase: type IV collagen 
NC1 and triple helix-rich domains. Equimolar amounts of type IV 
collagen (60 ttg/ml) (e), NCI domain (20/~g/ml) (D), and triple 
helix-rich domain (52/~g/ml) (zx) were coated onto 96-well plates 
and increasing concentrations of ~25I-Hep-I were added and al- 
lowed to incubate for 2 h at 37°C. The radioactivity that remained 
bound after incubation and washes was plotted per concentration 
of added peptide. 
hydropathy value, bound to a much lesser extent to type IV 
collagen (maximal binding is '~20 ng) (Fig.  1 A). However, 
the obtained binding could not be competed even by a 400- 
fold excess of unlabeled control peptide  1,  and,  therefore, 
this binding should not be specific (Fig.  1 A).  In this type 
of direct and competition-binding assay we used BSA coated 
onto plastic to test for nonspecific binding of the peptide. 
This binding was  found to be <2 % of the total binding of 
the peptide to type IV collagen-coated substrata at all the 
concentrations used (data not shown),  and was subtracted 
accordingly before plotting the data  (Fig.  1 A).  Scatchard 
analysis of the solid-phase binding data (Fig. 1 B) suggested 
that a single class of affinity sites existed in type IV collagen 
for binding to peptide Hep-I, with an apparent Kd of 1.66 
nM (R  =  0.9209; p<<0.001). 
In another series of experiments, the binding of increasing 
concentrations of ~25I-Hep-I to: type IV collagen, NC1 do- 
main and triple helix-rich domain coated onto plastic wells 
was  tested and compared.  Under our experimental condi- 
tions, radiolabeled peptide Hep-I bound only to intact type 
IV collagen but failed to bind to either the NC1- or triple he- 
lix-rich domains (Fig. 2). Thus, the integrity of type IV col- 
lagen was apparently required for interaction(s) with peptide 
Hep-I. 
The effect of peptide Hep-I on the process of polymeriza- 
tion of type IV collagen was then tested by the technique of 
rotary  shadowing  in  double-blind  experiments.  We  and 
others  have  previously  reported  that  upon  incubation  at 
37°C, type IV collagen in neutral buffers forms a hexagonal 
quasi-regular structure (30,  38).  For this type of assembly 
to occur, the NCI domain is required to bind along the length 
of the rodlike part of type IV collagen so that subsequent 
lateral associations can form in a zipperlike manner (30, 37). 
This latticelike structure was quantitated and was observed 
to represent '~74% of the total type IV collagen present, the 
rest being either in dimeric/monomeric form or random ag- 
gregates. In the presence of NC1 domain, the lattice forma- 
tion was decreased to ,'~30%, an indication that the NC1 do- 
main  bound  to  type  IV  collagen  and  competed  for  the 
binding of other adjacent type IV collagen molecules and 
lateral assembly as we reported previously (30,  31).  When 
type IV collagen solutions were coincubated in PBS at 37°C 
with peptide Hep-I at a range of  concentrations per milliliter, 
the lattice formation was also decreased, thus mimicking the 
effect of the intact NC1 domain (Fig. 3 C). Most of type IV 
collagen in the presence of peptide Hep-I occurred either in 
a dimeric/monomeric form or as random aggregates (Fig. 3 
B).  Two other NCl-derived,  control peptides,  peptides 4 
(data not shown), and 1, did not have any effect on lattice for- 
mation when each was  separately incubated with type IV 
collagen (Fig. 3, A and C). 
Further evidence for a specific interaction between type IV 
collagen and peptide Hep-I and an effect on type IV collagen 
assembly was obtained by turbidimetric assays.  In these as- 
says, the turbidity of type IV collagen alone or in the pres- 
ence of added NC1 domain with and without peptide Hep-I 
or other control peptides was assessed. When prewarmed at 
37°C, type IV collagen (250/~g/ml) raised turbidity to a pla- 
teau value, with a typical curve (Fig. 4) (30,  38). Addition 
of isolated NC1  domain (20 ~tg/ml) resulted in "o30% de- 
crease  of the  maximal  turbidity  of type IV  collagen,  as 
reported previously (30, 31). When peptide Hep-I was added 
in the incubation mixture, it further suppressed the develop- 
ment of turbidity by an additional ~20% (the total decrease 
of the  maximal  turbidity  was  therefore ~50%)  (Fig.  4). 
Thus, peptide Hep-I had an effect similar to that of intact 
NCI domain competing for lateral assembly of  type IV colla- 
gen  in  turbidity experiments.  Two other control peptides 
from the al(NC1) chain, peptide 1 and peptide 4 (Table I), 
did not have any additive effect on the maximal turbidity of 
prewarmed type IV collagen-NC1 domain mixtures (Fig. 4). 
In summary, with the above-mentioned approaches: solid 
phase binding assays,  turbidimetry and rotary shadowing, 
and peptide Hep-I appeared to specifically bind to intact type 
IV collagen and also inhibited the assembly process of this 
basement membrane collagen to a networklike polymer. 
Role of Peptide Hep-I in Adhesion and Spreading of 
Bovine Aortic Endothelial Cells 
In  solid phase-binding  experiments, the ability of peptide 
Hep-I to promote cell adhesion was tested in comparison to 
intact type IV collagen and the NC1  domain.  As reported 
previously (16),  both type IV collagen and also the isolated 
NC1  domain promoted the  adhesion of bovine aortic en- 
dothelial cells in a dose-dependent manner. A concentration 
of type IV collagen as low as 0.05/zg/well resulted in ~20 % 
adhesion  whereas  at  5  /zg/well  ,~40%  adhesion of added 
35S-labeled  endothelial  cells  occurred.  Intermediate  con- 
centrations of type IV collagen also resulted in a similar de- 
gree  of adhesion.  Similarly,  NC1  domain  coated  at  0.5 
/zg/well  resulted  in  ~25 %  adhesion  of added  endothelial 
cells. At a coating concentration of 2.5 #g/well and 5 /~g/ 
well, 30-35 % endothelial cell adhesion was observed. Pep- 
tide Hep-I coated at the above mentioned concentrations of 
0.5, 2.5, and 5/~g/well supported the adhesion of 'M0% of 
added 35S-labeled endothelial cells. Under our experimental 
conditions, 1-2% of the added peptide was bound to the plas- 
tic (19).  When coated at higher concentrations (10-25/zg/ 
well) a higher percentage of adhering cells (~25 %) was ob- 
tained. Coupling of  the peptide to ovalbumin did not enhance 
cell adhesion (data not shown). A control peptide with simi- 
lar length and hydropathy value, peptide 1, either uncoupled 
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Figure 3.  Rotary shadowing  images of type IV collagen  incubated 
for 7 h at 37°C in the presence of: (A) 800 ,ug/ml control peptide 
1; (B) 200 #g/ml peptide  Hep-I; (C) diagrammatic representation 
of the percentage of fields containing lateral associations  in various 
samples  of type IV collagen that was incubated  at 37°C and then 
examined  by rotary shadowing  for network formation.  Maximal 
network formation by type IV collagen only was considered to rep- 
resent  100% of lateral  associations  under the experimental  condi- 
tions used.  (i) Type IV collagen containing 0, 25,  100, 200,  and 
800  #g/ml peptide  Hep-1;  and  ([])  type IV collagen  containing 
control peptide  1 (800/~g/ml).  A minimum of 150 fields/specimen 
were  scanned  in  double-blind  experiments.  Standard  deviation 
was ~<5%. 
or coupled to ovalbumin, did not promote any significant cell 
adhesion. 
To further assess  the specificity of the  interaction(s)  be- 
tween peptide Hep-I and endothelial cell surfaces, the bind- 
ing  of  bovine  aortic  endothelial  cells  to  intact  type  IV 
collagen-coated substrata  was competed by increasing con- 
centrations of peptide Hep-I. In the presence of as low as 0.2 
#g peptide (4/zg/ml) Hep-I, a ~25 % decrease of endothelial 
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Figure 4. Turbidity  of type IV collagen in the absence or presence 
of NC1 domain and various peptides.  The following mixtures  were 
examined  and compared for the development of turbidity at 360 
rim:  type  IV  collagen  (250  /~g/ml) ([]);  type  IV  collagen  (250 
~tg/ml) containing NC1 domain (20 ttg/ml)  (.); and, in addition, 
either peptide  Hep-I (100/~g/ml)  (O) or any of the control pep- 
tides,  either peptide  1 (100 /~g/ml) (n) or peptide  4  (100/,g/ml) 
([]).  The  temperature  was  maintained  at  37°C  throughout  the 
course of the experiment. 
cell adhesion occurred (Fig.  5).  The maximal inhibition of 
adhesion to type IV collagen was '~50%  and was reached 
when "~5 #g (100/zg/ml) of the specific peptide was coin- 
cubated with endothelial cells (Fig. 5). As a control, we used 
in the same range of concentrations peptide GRGDSP, which 
as we previously reported, did not have any effect on the pro- 
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Figure 5. Inhibition of the binding of bovine aortic endothelial  ceils 
to solid-phase  immobilized type IV collagen by various peptides in 
solution.  [35S]Methionine-labeled  cells  were  incubated  with  in- 
creasing concentrations of peptide  Hep-I (t),  peptide  GRGDSP 
(o), or peptide  1 (A) for 15 min at room temperature.  Approxi- 
mately 5,000 cells/peptide  concentration were then added per well 
in  triplicate  and  were  further  incubated  with  type IV  collagen 
(coated onto plastic at 10/zg/ml),  for 60 min at 37°C. The remain- 
ing radioactivity after incubation and washes was expressed as per- 
cent ceils bound per added concentration of inhibitor (highest con- 
centration  of inhibitor-peptide  used: 500 ~g/ml or 25 #g/well).  The 
amount of cells bound in the absence of inhibitor was considered 
to represent maximal (100%) binding.  Background binding to BSA 
was <2 % and was subtracted. 
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Figure 6. Inhibition of the binding of bovine aortic endothelial cells 
to solid-phase, immobilized NCI domain by various peptides in so- 
lution.  [35S]Methionine-labeled ceils were incubated with increas- 
ing concentrations  of peptide Hep-I (m) or peptide GRGDSP (o) 
for 15 min at room temperature. Approximately 5,000 cells/peptide 
concentration were then added per well and were further incubated 
with NC1 domain-coated in plastic wells (20 #g/ml) for 60 min at 
37°C. The remaining radioactivity after incubation and washes was 
expressed as percent of cells bound per added concentration of in- 
hibitor, per well (highest concentration of inhibitor used was 500 
/~g/ml). The amount of cells bound in the absence of inhibitor was 
considered  to  represent  maximal  binding  (100%). Background 
binding to BSA was <2 % and was subtracted. 
cess of adhesion of bovine aortic endothelial cells to type IV 
collagen  (16)  (Fig.  5)  and  peptide  J-61,  another  RGD- 
containing  peptide  from  the  al(IV)  (Table  I)  (data  not 
shown). Additionally, peptide 1 (Table I), a peptide of simi- 
lar length and hydropathy value to peptide Hep-I, also had 
no effect on  the  adhesion  of endothelial  cells  to  type IV 
collagen-coated substrata (Fig.  5). 
The binding of endothelial  cells to NC1  domain-coated 
substrata was dramatically decreased following preincuba- 
tion of the cells with  increasing concentrations  of peptide 
Hep-I. Even in the presence of 0.1  gg (2 ttg/ml) of peptide 
Hep-I, the final cell adhesion was *50% (Fig. 6), and, with 
increasing  peptide  concentrations,  the  adhesion  gradually 
decreased further; at a concentration of 1 #g (20/xg/ml) pep- 
tide  Hep-I the  obtained  adhesion  was  as  low  as  20%  or 
slightly less (Fig. 6). Control peptide GRGDSP did not have 
any  effect on  endothelial  cell  adhesion  to  NC1  domain- 
coated substrata following coincubation with the endothelial 
cells (Fig.  6). 
Another approach that was used to confirm the specific na- 
ture of binding of peptide Hep-I to bovine aortic endothelial 
cells was the binding of ~25I-Hep-I in solution to the surface 
of these cells. This binding was shown to be dose-dependent 
and saturable (Fig.  7).  Furthermore,  the binding of radio- 
labeled  peptide  was  competed by an  excess  of unlabeled 
peptide (maximal excess: 400-fold),  further confirming the 
specificity of interaction(s) between endothelial cell surfaces 
and peptide Hep-I (Fig.  7).  Peptide ET-2, another control 
peptide from the al(IV) (Table I), failed to compete for the 
binding of ~25I-Hep-I to endothelial cells (Fig.  7). 
In cell  spreading experiments,  ~92.8%  of attached en- 
dothelial cells were spread within 30 min when intact type 
IV collagen was the substrate (Fig. 8 A), and the percentage 
did not change substantially throughout the time course of 
the study. The spreading achieved on substrates of peptide 
Hep-I was  ~60%  of attached cells by 30 min (Fig.  8  C), 
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Figure 7. Binding of 125I-peptide Hep-I to bovine aortic endothelial 
cells and competition of the binding of ~25I-peptide Hep-I to bo- 
vine aortic endothelial cells by unlabeled peptides in solution. Un- 
labeled  cells  were mixed with increasing  concentrations  of t25I- 
Hep-I in solution and were incubated for 20 min at 4°C  (highest 
concentration of peptide used was 2 mg/ml). The cells were then 
pelleted  and  washed  and bound  radioactivity  was expressed  as 
micrograms  of peptide  bound  per microgram of added  peptide 
(-). In addition, a constant amount of ~2I-Hep-I  (5 ttg) was mixed 
with increasing concentrations  of either unlabeled peptide Hep-I 
(~) or unlabeled control peptide ET-2 (o) (maximal excess of unla- 
beled peptide used was 400-fold).  Unlabeled ceils were then in- 
cubated with each of the peptide mixtures for 20 rain at 4°C. The 
cells were then pelleted and washed and the remaining radioactivity 
was plotted as percent of maximal binding per microgram of inhibi- 
tor added.  Maximal binding was the binding obtained in the ab- 
sence of inhibitor. 
83 % by 60 min and 84% by 90 min. Thus, a longer time was 
required for cells to attain maximal spreading in the case of 
peptide Hep-I-mediated adhesion when compared to intact 
type IV collagen-mediated adhesion.  Adhesion and spread- 
ing to BSA at all time intervals were minimal (1.7-2.2%  of 
added endothelial cells adhered)  (Fig.  8 B). 
The Effect of Heparin on Endothelial Cell Binding to 
~pe IV Collagen, NC1 Domain and Peptide Hep-I 
Because peptide Hep-I (from the al[NC1] chain) as well as 
the  NC1  domain  and  intact  type  IV collagen  specifically 
bound heparin (19),  we tested the effect of heparin on the 
binding of endothelial  cells to type IV collagen,  NC1  do- 
main, and peptide Hep-I-coated substrata. We observed that 
the binding of endothelial cells to intact type IV collagen at 
all concentrations used (1-60/~g/ml) was unaffected even at 
the highest concentration of glycosaminoglycans used (Fig. 
10)  (10  mg/ml,  while the  cells remained viable based  on 
trypan  blue  exclusion).  In  contrast,  the  binding  of  en- 
dothelial cells to isolated, solid phase-immobilized NC1 do- 
main was substantially decreased in the presence of increas- 
ing concentrations of heparin.  A  significant suppression of 
cell  adhesion  ('~50%)  was  observed  in  the  presence  of 
~0.300  #g/ml (15 #g/sample) heparin (Fig.  9).  Chondroi- 
tin/dermatan sulfate glycosaminoglycan side chains also had 
a  similar effect (data not shown). 
Cell adhesion to peptide Hep-I was similarly suppressed 
by heparin (Fig.  9),  whereas chondroitin/dermatan  sulfate 
was effective in inhibiting cell adhesion only at the highest 
concentration  used,  a  concentration  of  10  mg/ml  (500 
#g/sample) (data not shown). 
The Journal of Cell Biology, Volume  111,  1990  1588 Figure 8. Light micrographs of bovine aortic endothelial cells following a 30-min adhesion to type IV collagen (A), BSA (B), and peptide 
Hep-I (C).  Type IV collagen was coated at 10 #g/ml, BSA at 5 ttg/ml and peptide Hep-I at 20/~g/ml.  Magnification at 70. 
Discussion 
In this report, two distinctive functions ofpeptide Hep-I (Ta- 
ble I)  from the al(NC1)  chain of type IV collagen are de- 
scribed.  A major function of this peptide is to specifically 
bind to type IV collagen. This binding results in inhibition 
of assembly of type IV collagen assessed both by turbidime- 
try and rotary shadowing. 
We had reported earlier that the NC1 domain was neces- 
sary for the initiation of lateral associations by mediating the 
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Figure  9.  3~S  Methionine-labeled endothelial  cells  were  mixed 
with increasing concentrations of heparin and were then added to 
type IV collagen-plated at 60 #g/ml (o); NC1 domain plated at 60 
/zg/ml (*); and peptide Hep-I plated at 200/~g/rrd (t~). The mix- 
tures were incubated for 60 rain at 37°C. The radioactivity remain- 
ing after incubation and washes was  expressed as percent cells 
bound per concentration after added competitor. The radioactivity 
obtained in the absence of competitor was considered to represent 
maximal binding (100%). 
binding of adjacent collagen molecules (30). After diabetic 
modifications by in vitro nonenzymatic glucosylation of the 
NC1 domain, the ability of this domain to inhibit lateral as- 
sociations by type IV collagen was perturbed (31).  Such a 
functional impairment should lead to an altered assembly of 
glucosylated type IV  collagen in  newly synthesized base- 
ment membranes.  Because lysine residues are the primary 
targets for nonenzymatic glucosylation (5, 6, 11), we selected 
three peptides from the al(NC1) chain that contained all the 
lysine residues (a total of five) present in this domain of the 
al(IV) chain (25, 28, 29). It was reasoned that if at least one 
of these lysine residues was part of a sequence binding to type 
IV collagen and if it were modified by glucosylation, this 
might account at least in part for the impairment of the func- 
tion  of glycated NC1  domain.  The three al(NC1)-derived 
peptides that were synthesized were peptides 1, 4, and Hep-I 
(Table I). These peptides were then tested for binding to type 
IV collagen, and only peptide Hep-1  was found to specifi- 
cally bind to this glycoprotein. The specificity of the interac- 
tion was demonstrated by the saturable nature of the binding 
and the efficient competition of the binding of 12SI-Hep-I to 
type IV collagen by an excess of unlabeled Hep-I. The affin- 
ity of the interaction(s) between type IV collagen and peptide 
Hep-I  was  substantial  as  indicated  by the obtained Kd of 
1.66 nM. This specific peptide, but not any of  the other tested 
NCl-derived peptides, could also mimic the effect of intact 
NC1 domain when used at a range of concentrations (25-800 
/~g/ml) by competing for development of turbidity and lattice 
formation in rotary shadowing images. Thus, the sequence 
represented in peptide Hep-I should probably be a major mo- 
lecular determinant in  the  noncollagenous domain that  is 
used for recognition by type IV collagen. It is worth noting 
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Hep-I. Isolated dimeric NC1  domain failed to bind to this 
peptide, indicating that this sequence does not bind to itself 
or any other sequence of the NC1 domain. In addition, pep- 
sin-derived type IV collagen also failed to bind to this spe- 
cific  peptide  under  our  experimental  conditions.  Pepsin- 
derived type IV collagen lacks the NC1  domain but should 
also have several discontinuities of the triple helix-rich seg- 
ment at least partially disrupted at the sites of cleavage by 
pepsin (4, 19). Therefore, the obtained data indicate that in- 
teractions between peptide Hep-I and the rodlike part of type 
IV collagen should probably occur primarily at sites where 
the triplet motif is interrupted by noncollagenous sequences. 
Peptide Hep-I was also described in a previous report to 
specifically bind  to heparin and  to  inhibit the binding  of 
heparin to type IV  collagen in  a  dose-dependent manner 
(I9). Because heparin-related structures often occur in hepa- 
ran sulfate proteoglycan and,  in particular,  because aortic 
endothelial ceils have been reported to contain sequences 
identical to heparin in their heparan  sulfate proteoglycan 
(24),  we examined interactions between bovine aortic en- 
dothelial cells and peptide Hep-I.  We had previously re- 
ported that  aortic endothelial cells  preferably adhered  to 
type IV collagen and isolated NC1 domain as compared to 
fibronectin or laminin (16). In the present study, the adhesion 
of bovine aortic endothelial cells to substrates of type IV col- 
lagen, NC1 domain, and peptide Hep-I was compared. Pep- 
tide Hep-I was able to promote adhesion of this cell type in 
a dose-dependent manner (other cell types including micro- 
vascular endothelial cells and murine melanoma cells also 
adhered in preliminary observations). This cell adhesion was 
apparently specific for this sequence since it was  not sus- 
tained in the presence of control peptides.  Of specific in- 
terest is the lack of inhibition of adhesion of cells to type IV 
collagen and the NC1 domain by RGD-containing peptides 
that efficiently inhibit cell attachment to fibronectin (14-16, 
27). Thus, these data confirm our previous report (16) in that 
they indicate an attachment to type IV collagen which is in- 
dependent of RGD-containing sequences (including an RGD 
containing peptide from the al[IV], Table I). However, the 
adhesion of cells to both the intact type IV collagen and the 
isolated NC1 domain was dependent on peptide Hep-I; a par- 
tial inhibition (~50%) of endothelial cell adhesion to intact 
solid phase-type IV collagen was obtained under our exper- 
imental conditions. This finding indicates that multiple de- 
terminants in type IV collagen may interact with endothelial 
cell surfaces and that peptide Hep-I is one of them. A much 
higher inhibition of cell adhesion (~80%) was obtained on 
substrates coated with NC1 domain. Therefore peptide Hep- 
I should be a major determinant for cell recognition in the 
NC1 domain. Radiolabeled peptide Hep-I was also found to 
bind in solution to endothelial cells in a dose-dependent and 
saturable manner. An excess of unlabeled peptide efficiently 
competed for this binding, confirming the specificity of this 
interaction. The site(s) recognized by peptide Hep-! on cell 
surfaces remains to be elucidated. Because peptide Hep-I 
also bound heparin, the possibility exists that heparin-related 
side chains of one or more species of cell surface-heparan 
sulfate proteoglycan may partially mediate binding to the se- 
quence represented in peptide Hep-I. This possibility is rein- 
forced by the competition of adhesion of endothelial cells to 
NC1  domain and this  specific peptide,  in the presence of 
heparin. Because a substantial suppression of cell binding to 
NC1 coated onto plastic was obtained in the presence of hep- 
arin and chondroitirddermatan sulfate glycosaminoglycan  side 
chains, it seems likely that the NC1  domain may primarily 
mediate charge interactions between basement membrane 
collagen and endothelial cells. However, our experiments do 
not exclude the possibility that the protein core of one or 
more cell surface proteoglycans or additional glycoproteins 
or other components also serve for binding to peptide Hep-I, 
the NC1 domain or type IV collagen. The lack of competi- 
tion by glycosaminoglycans for the binding of endothelial 
cells to intact type IV collagen implies that charge-mediated 
interactions (attributed to the side chains of cell surface pro- 
teoglycans) represent only one of many possible interactions 
and that other binding events should also occur which need 
to be explored. 
Another point of interest was the ability of peptide Hep-I 
to sustain not only endothelial cell adhesion but a substantial 
cell spreading as well.  Interactions between cells and ex- 
tracellular matrix components including type IV collagen 
should comprise a series of events in a temporal scheme: (a) 
adhesion occurs;  and  then  (b)  cytoskeletal reorganization 
that leads to cell spreading, with the formation of focal adhe- 
sion and focal contacts (7,  35).  Peptide Hep-I was able to 
promote the cytoskeletal organization required for spreading 
to occur, although a longer time interval was required when 
compared to intact type IV collagen. 
The ability of a distinctive amino acid sequence of a large 
extracellular molecule, like basement membrane collagen, 
to perform more than one function could possibly allow for 
a multiplicity of regulatory events. For example, depending 
upon the local or temporal requirements, affinities of interac- 
tions, and availability of reacting candidates, this microdo- 
main could have the flexibility to participate in a variety of 
possible interactions that in turn would result in a variety of 
structures. Thus, by the use of the same repertoire of reac- 
tants,  structural and functional diversity could emerge de- 
pending upon different interactions (9). This then could ac- 
count at least in part for the multiplicity of structure and 
function of different basement membranes. 
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